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Abstract 
Background: Melanoma cells develop adaptive responses in order to cope with particular conditions of tumor 
microenvironment, characterized by stress conditions and deregulated proliferation. Recently, the interplay between 
the stress response and the gene expression programs leading to metastatic spread has been reported.
Methods: We evaluated levels and localization of eIF2α/peIF2α in V600BRAF and wtBRAF metastatic melanoma cell 
lines by means of western blot and confocal microscopy analyses. Furthermore, we performed a sequence analyses 
and structure and dynamics studies of eIF2α protein to reveal the role of eIF2α and its correlations in different path-
ways involved in the invasive phase of melanoma.
Results: We found peIF2α both in cytoplasm and nucleus. Nuclear localization was more represented in V600BRAF 
melanoma cell lines. Our studies on eIF2α protein sequence indicated the presence of a predicted bipartite NLS as 
well as a nuclear export signal NES and an S1 domain, typical of RNA interacting proteins. Furthermore, we found high 
levels of transcription factor EB (TFEB), a component of the MiT/TFE family, and low β-catenin levels in V600BRAF cells.
Conclusions: Based on our results, we suggest that peIF2α nuclear localization can be crucial in ER stress response 
and in driving the metastatic spread of melanoma, through lysosomal signaling and Wnt/β-catenin pathway. In con-
clusion, this is the first evidence of nuclear localization of peIF2α, representing a possible target for future therapeutic 
approaches for metastatic melanoma.
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Background
Melanoma is one of the skin tumors with increasing inci-
dence in the general population [1]. It is a particularly 
severe form of skin cancer due to its ability to metasta-
size, even several years after the removal of the primary 
melanoma, and to its resistance to medical therapies in 
case of metastasis. One of the peculiar characteristics of 
melanoma is the involvement of several molecular path-
ways in its development and progression. This feature is 
associated to diverse escape mechanisms to target thera-
pies (i.e. anti-BRAF) for the metastatic disease.
The most recent knowledge of melanoma biology 
focuses on the role of endoplasmic reticulum (ER) stress, 
autophagy and translational reprogramming. In brief, 
tumor microenvironment conditions, characterized by 
stress stimuli and a push to fuel continue proliferation, 
induce the development of cellular adaptive responses. In 
particular, these stress signals induce the activation of the 
unfolded protein response (UPR) [2–4], and translational 
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block, in order to avoid the accumulation of proteins 
entering the ER. The translational block is achieved 
through the phosphorylation of the alpha subunit of 
eukaryotic translation initiation factor 2 (eIF2α) which is 
one of the key regulator of the Integrated Stress Response 
(ISR). ISR is a common adaptive pathway, activated in 
response to diverse stress stimuli, in order to restore cel-
lular homeostasis [5]. The central core of ISR response 
is eIF2, a heterotrimeric protein constituted by α, β and 
γ subunits, an essential factor involved in the initiation 
phase of eukaryotic translation. eIF2 is a G-protein that, 
in its active GTP-bound form, interacts with Met-tRNAi 
promoting its binding to the 40S ribosomal subunit and 
determining the correct localization on the start codon. 
The codon-anticodon interaction triggers GTP hydroly-
sis, whereby an inactive eIF2-GDP complex is released. 
eIF2 reactivation is catalyzed by the recycling factor 
eIF2B that allows GDP/GTP exchange. Indeed, the recy-
cling of the factor can be inhibited by the phosphoryla-
tion of its alpha subunit at Ser 51. In its phosphorylated 
form, eIF2 behaves as a competitive inhibitor of eIF2B, 
preventing GDP/GTP exchange and thereby reactiva-
tion of eIF2. eIF2 phosphorylation is triggered by various 
stress conditions, such as viral infection or nutrient dep-
rivation, which lead to the activation of specific kinases 
(PKR, PERK, GCN2, HRI). The phosphorylation of eIF2α 
determines an increase in the expression of the transcrip-
tion factor ATF4, a key component of the ISR, in order 
to promote cellular recovery. ATF4 is a transcription fac-
tor of the ATF/CREB family that regulates the expression 
of genes involved in oxidative stress, amino acid synthe-
sis, differentiation, metastasis and angiogenesis and it is 
induced by stress signals including anoxia/hypoxia, ER 
stress, amino acid deprivation, and oxidative stress [6].
There are evidences that eIF2α expression levels and 
phosphorylation status increase in tumours compared 
with normal tissue [7–11]. In melanoma, it has been pre-
viously demonstrated that in V600BRAF metastatic mel-
anoma cell lines eIF2α is more phosphorylated, respect 
to wtBRAF melanoma cells [12].
A recent study [13] shows the important interplay 
between the ISR and the gene expression programs lead-
ing to metastatic spread, regulated by MITF [13]. MITF is 
a transcription factor that drives the expression of genes 
involved in cell differentiation, proliferation and survival. 
It plays an important role in melanocyte development by 
regulating the expression of genes implicated in melanin 
production and its levels have been associated to mel-
anocytes transformation to melanoma [14, 15]. One of 
the components of the MITF/TFE family of transcrip-
tion factor [16] is TFEB, well-known for its key role in 
autophagy activation and recently proposed as a master 
regulator of ISR [5].
Several pathways involved in cellular proliferation, 
translational reprogramming, together with molecular 
adhesion variations (i.e. β-catenin), seem to be the key 
events that drive gene expression to an invasive phase of 
melanoma [12, 13]. Because of its pivotal role in trans-
lation initiation, eIF2α is the main target of translational 
regulation mechanisms. Thus, the aim of the current 
work is to perform a detailed evaluation of eIF2α/peIF2α 
levels and location. In addition, we estimated the corre-
lation of eIF2α with different pathways involved in the 
invasive phase of melanoma in an in  vitro melanoma 
model.
Materials and methods
Cutaneous melanoma cell lines
Hmel1 and M3 were metastatic melanoma cell lines 
extracted in our laboratory and proceeding from patients 
coming from the south of Italy. These cell lines have 
been described in Zanna et  al. [17], and Ferretta et  al. 
[12]. Hmel1 and M3 represent the metastasis harboring 
V600BRAF mutation. HBL is a metastatic melanoma cell 
line, kindly provided by Ghanem Ghanem. It was used 
as control cell line because it is wt for BRAF. In addition, 
hmel9 cells, non-metastatic V600BRAF-mutated, previ-
ously described [12, 17] were used.
Western blots and cell fractioning
Cells were lysed as described in Herraiz et al. [18]. Bicin-
choninic acid reagent, from Sigma Aldrich (St. Louis, 
MO), was used to quantify proteins. Electrophoresis and 
Western blots were performed as described in  Ferretta 
et  al.  [12]. 30–50  µg of the cell lysate were loaded on a 
SDS-PAGE (10% or 13% for TFEB) and transferred to a 
nitrocellulose membrane (GE Healthcare, Little Chalfont, 
UK) for Western Blot analysis. The polyclonal antibodies, 
anti-eIF2α and anti-peIF2α Ser 51 were purchased from 
Cell Signaling Technology (Danvers, MA); the polyclonal 
anti βcatenin antibodies and the secondary antibody-
HRP conjugated were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). The mouse anti Flag M2 
monoclonal antibody was from Sigma. TFEB antibod-
ies and the anti-mouse HRP secondary antibody were 
from Millipore (Burlington, Massachusetts, US). Pro-
tein loading was assessed reprobing the blots with anti-
βtubulin antibodies (Sigma Aldrich, St. Louis, US). All 
the antibodies were used according to the manufacturer’s 
instruction. Chemioluminescence was detected using 
the Super signal western Pico Pierce or the chemilumi-
nescent Pierce ECL Western Blotting Substrate (Thermo 
Scientific, IL). The densitometric profiles were performed 
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using a Image lab 5.2 imaging software (Bio-Rad Labora-
tories) or Bio-rad GS 800, and analyzed by the Quantity 
One Software, all purchased by Bio-Rad Laboratories 
(Hercules, CA).
The M3 cell fractioning was performed as previously 
described in Zanna et  al. [19], obtaining nuclear and 
cytoplasmic fractions used for western blot analyses. The 
purity of the nuclear and cytosolic fractions was verified 
by the presence of βtubulin immunoreactive band after 
immunoblotting with anti-βtubulin antibody).
Confocal microscopy
Cells grown on coverslips and washed with PBS, fixed 
with 4% paraformaldehide, and blocked with 20 mM gly-
cine. Cells were permeabilized with 0.5% Igepal CA-640 
in PBS. Cells were stained with anti-eIF2a and the anti-
peIF2α diluted in PBS containing 1% BSA. Goat anti-
rabbit Alexa 488 conjugated antibody Molecular Probes 
(Invitrogen, CA) in PBS/1%BSA was used. Incubations 
were performed at 4  °C. Samples were examined with a 
Nikon confocal microscope (Nikon Corporation, Tokyo, 
Japan).
eIF2α cloning in a pCMV‑flag vector
eIF2α molecular cloning was performed on pCVM-flag 
(Sigma Aldrich, St. Louis, MO). eIF2α coding sequence 
was obtained by M3 cDNA by PCR using a proofreading 
polymerase (Kapa Hifi, Roche, Basilea Switzerland) and 
the primers eIF2αHINDIIFw (5′-CGC AAG CTT CCG 
GGT CTA AGT TGT AGA-3′) and eIF2αXbaIRv (5′-CGC 
TCT AGA CAC AAA GTT AAT CTT CAGC-3′), purchased 
from Sigma. The PCR product and pCMVflag were 
digested for HindIII and XbaI restriction enzymes (Pro-
mega, Wisconsin, US), loaded on a 1% preparative aga-
rose gel and eluted using the extraction kit purchased by 
RBC Biosciences (New Taipei, Taiwan). The ligation of 
the pCMV vector with the 947  bp PCR eIF2α was per-
formed o.n. at 4  °C using a T4 DNA ligase (Promega) 
according to the manufacturer’s instructions. Ligations 
were used to transform Top10 chemically competent 
E. coli (Thermo Fisher Scientific, Waltham, Massachu-
setts, US), the colonies were selected and minipreps were 
screened by digestion with HindIII and XbaI. The pCM-
Vflag and pCMVflag-eIF2α were used to transfect 293T 
cells using lipofectamine 2000 transfection reagent (Inv-
itrogen, Meridian Rd, Rockford, IL), according to manu-
facturer’s instructions.
eIF2α structural analysis
The solution NMR structure of the alpha subunit of 
human eIF2 1Q8  K [20] was obtained from the RCSB 
PDB [21] available at http://www.rcsb.org. From each of 
the reported models in the 1Q8 K entry a separate pdb 
file was obtained by Tcl scripting in VMD [22]. These pdb 
structures were processed as described in [23, 24]. Briefly, 
structures in the data set were aligned to a reference 
by a rotation and translation matrix, by a Tcl script in 
VMD. The Cartesian coordinates of alpha-carbon atoms 
of the rotated structures were extracted and arranged 
in a matrix form in which each row represents a struc-
ture, and principal component analysis (PCA) was per-
formed on the normalized data [25–28]. To visualize the 
obtained principal displacement modes encoded in the 
whole 1Q8K PDB entry, a nmd file was constructed [23, 
24], which was analyzed by the VMD plug-in NMWiz 
[29].
The prediction of nuclear export signals (NESs) in the 
sequence of the alpha subunit of human eIF2 has been 
performed at the NetNES 1.1 Server [30]. Protein–pro-
tein interactions were obtained from the BioGridreposi-
tory [31, 32].
The prediction of eIF2α nuclear localization signals 
(NLS) were performed using the program cNLS Map-
per (available at http://nls-mappe r.iab.keio.ac.jp/cgi-bin/
NLS_Mappe r_form.cgi) using a cutoff 4. An additional 
analysis of the eIF2α functional domains has been per-
formed using the SMART program (http://smart .embl-
heide lberg .de/).
Results
peIF2α localization in melanoma cell lines
In the present work, in order to provide meaningful 
information about the subcellular localization of peIF2α 
and eIF2α, we performed studies with specific antibodies 
against the phosphorylated (peIF2α) and the total eIF2α 
form (eIF2α) comparing metastatic melanoma hmel1 
and M3 (V600BRAF) with HBL cell lines (wtBRAF). The 
analysis of the eIF2α subcellular localization revealed a 
prevalent cytoplasmic localization, as compared to the 
nuclear compartment without significant differences 
among the different metastatic melanoma cell lines 
(Fig.  1a). Analysis of the peIF2α, beyond the cytoplas-
mic localization, revealed a nuclear staining in all the 
melanoma cell lines (Fig.  1a). This nuclear localization 
was more evident in V600BRAF M3 and hmel1 mela-
noma cell lines (Fig. 1a), as compared to wtBRAF HBL. 
To avoid the possibility that such result could be due to 
a non-specific antibody background, we performed a 
M3 cell fractioning separating the cytoplasmic from the 
nuclear fraction. The western blotting analysis using total 
eIF2α or peIF2α antibody on the cytoplasmic and nuclear 
M3 cellular fractions confirmed that the peIF2α was pre-
sent both in the nucleus and in the cytoplasm (Fig. 1b), 
even if the total eIF2α was more abundant in the cyto-
plasmic fraction. The purity of the fractions was checked 
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by SDS-PAGE and western blotting analysis using an anti 
β-tubulin antibody (Fig. 1b).
As reported in Ferretta et  al. [12] the non-metastatic 
V600BRAF hmel9 cell line, showed a lower level of 
peIF2α, as compared to metastatic melanoma cells [12]. 
Therefore, we extended the analysis of peIF2α cytoplas-
mic and nuclear localization to hmel9 cell line, find-
ing lower nuclear level of peIF2α in non-metastatic 
V600BRAF hmel9 cells, as compared to metastatic 
V600BRAF M3 cells (see Additional file 1: Fig. S1).
eIF2α sequence analysis and eIF2α‑flag expression 
and localization in 293T transfected cells
We investigated the eIF2α sequence to detect if there 
were some signal sequences for its entrance into the 
nucleus using the program cNLS mapper (http://nls-
mappe r.iab.keio.ac.jp/cgi-bin/NLS_Mappe r_form.cgi). 
The sequence analysis indicated the presence of a pre-
dicted bipartited NLS from the amino acid position 182 
to the 216 with a score of 4, 2 (Fig.  2a) which suggests 
the presence of a nuclear transporter that is able to rec-
ognize and bind eIF2α. Moreover, NES analysis using 
the NetNES 1.1 Server (http://www.cbs.dtu.dk/servi ces/
NetNE S/) revealed the presence of one nuclear export 
signal localized at pos 168 (Fig. 2a). Using SMART pro-
gram, we found an S1 domain typical of proteins inter-
acting with RNA [33].
A further evidence of eIF2α nuclear localization was 
achieved generating a construct in which eIF2α was 
expressed in the pCMV-flag vector under the control of 
the cytomegalovirus promoter and transfected in 293T 
cells. We analyzed the total extracts of the 293T trans-
fected with the pCMVflag-eIF2α expression vector in 
comparison with 293T cells transfected with the empty 
Fig. 1 eIF2α and phosphorylated eIF2α (peIF2α) translation factor localization in HBL (wtBRAF), hmel1 and M3 (V600BRAF) metastatic melanoma 
cell lines. a Confocal microscopy of localization of eIF2α and peIF2α using eIF2α (total form) or peIF2α (S51) antibodies in HBL (wtBRAF), hmel1 and 
M3 (V600BRAF) metastatic melanoma cell lines. b Western blotting analyses using eIF2α (total form) or peIF2α (S51) antibodies were performed on 
M3 nuclear and cytoplasmic fractions. The spot of β-tubulin demonstrates the purity of the nuclear and cytoplasmic fractions
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pCMV-flag vector. The exogenous eIF2α protein was 
expressed and recognized by western blotting using anti 
flag M2 antibody (Fig. 2b). To detect if eIF2α was trans-
ported from the cytoplasm (site of translation) into the 
nucleus, we isolated transfected 293T cytoplasmic and 
nuclear fractions (Fig. 2c). We performed a western blot 
using the anti-eIF2α antibody and we detected eIF2α-flag 
either in the nucleus and in the cytoplasmic fraction of 
the 293T transfected cells. The eIF2α-flag is expressed 
and recognized by the anti-eIF2α antibody (total form) 
like a slightly higher molecular weight protein, due to 
the presence of the flag, with respect to the endogenous 
eIF2α as shown in M3 cell line used as control (Fig. 2c). 
The fractions purity was determined using βtubulin as 
cytoplasmic marker (Fig. 2c).
eIF2α structure and dynamics
The solution structure of human eIF2α shows that the 
protein consists of two domains [20]. The N-terminal 
domain contains two distinct subdomains, an S1-type 
oligonucleotide/oligosaccharide binding fold and an 
alpha-helical region. The C-terminal domain has an 
alpha–beta fold that is similar to the C-terminal domain 
of the translation initiation factor eIF1B. These two 
domains are mobile relative to each other. Principal 
mode analysis of the deposited structure shows that the 
domains can rotate relative to one another exhibiting a 
twisting motion (see Additional file 2: Model 1). Moreo-
ver, a bending movement can be observed in which the 
two domains tend to approach (or move away) from one 
another (this is reported as Additional file  3: Model 2). 
Interestingly, recent data suggest that this last movement 
can be such as to bring the two domains into contact, and 
this closed conformation is disrupted by phosphorylation 
of S51 [34]. A predicted bipartite nuclear localization 
sequence (NLS) could be partially masked in the closed 
conformation of the protein. This region is reported in 
red in Fig. 3. The protein contains also a region where a 
(weak) nuclear export signal (NES) is expected (in yel-
low in Fig.  3). However, the functional significance of 
this NES is corroborated by the observation that a physi-
cal interaction between the protein and XPO1 has been 
reported experimentally [35]. Furthermore, a phospho-
rylation position is near this region (S158; the residues 
of serine that can be phosphorylated are highlighted in 
Fig. 3).
TFEB and βcatenin expression analysis
Since MITF/TFE family factors can regulate lysosomal 
signaling, including Wnt/β-catenin [36] we studied TFEB 
and βcatenin levels in V600BRAF melanoma cell lines. 
The transcription factor TFEB has been shown to control 
lysosomal biogenesis and autophagy by regulating the 
expression of several lysosomal and autophagy-related 
genes [37]. We analyzed basal levels of TFEB by semi-
quantitative western blotting analyses in HBL, hmel1 and 
M3 melanoma cell lines (Fig.  4a). We observed higher 
TFEB levels in hmel1 and M3 V600BRAF melanoma 
cell lines, as compared to HBL wtBRAF cells, in accord-
ance with our previous data [12] reporting higher levels 
of autophagy in V600BRAF melanoma cell lines with 
respect to wtBRAF cells.
We have already reported lower levels of βcatenin in 
various V600BRAF melanoma cell lines as compared to 
HBL wtBRAF cells [19]. In order to estimate β-catenin 
levels also in M3 cell lines, western blotting analyses were 
performed. In Fig. 4b we show a 2-times lower levels of 
βcatenin in V600BRAF hmel1 and M3 cell lines as com-
pared to HBL cells.
Discussion
In this study, we analyzed phosphorylation, localiza-
tion and conformational variations of the eIF2α subunit 
in metastatic melanoma cell lines with different BRAF 
mutational status, evaluating potential correlation 
with other pathways involved in the invasive phase of 
melanoma.
We have previously shown that peIF2α level is higher 
in cell lines proceeding from skin metastases (hmel1 and 
M3) than in cell lines from non-metastatic skin lesions 
(hmel9 and hmel11), harboring the V600BRAF mutation 
[12]. As a matter of fact, increased levels of peIF2α have 
been related to a worst melanoma prognosis [12] and to 
the invasive phase of melanoma [13].
The most striking result of the current work is the find-
ing, in metastatic cell lines, of a nuclear localization of 
peIF2α, as compared to non-metastatic cells (Additional 
file 1: Fig. S1).
(See figure on next page.)
Fig. 2 eIF2α sequence analysis and eIF2α-flag expression and localization in 293T transfected cells. a eIF2α sequence analysis using the program 
cNLS mapper. The sequence analysis indicated the presence of a predicted bipartited NLS from the amino acid position 182 to the 216. SMART 
program identify an S1 domain, typical of proteins interacting with RNA. NES analysis using the NetNES 1.1 Server revealed the presence of one 
nuclear export signal localized at position 168. b Western blotting of the total cell extract from 293T cells transfected with a pCMV-flag vector, 
pCMV-flag-eIF2α vector and not transfected cells stained with anti-Flag M2 antibody and anti-total eIF2α antibody. c Western blotting of the 
cytoplasmic and nuclear fraction from 293T cells transfected with pCMV-flag-eIF2α vector and M3 melanoma cells, stained using an anti-total eIF2α 
antibody. β-tubulin antibody was used to demonstrate the purity of the nuclear and cytoplasmic fractions
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Since eIF2α is well characterized as a translation initia-
tion factor, one would expect to find it in the cytoplasm 
and not in the nucleus. Nevertheless, another transla-
tion initiation factor, eIF4E, has already been reported to 
have a nuclear localization [8, 38–40]. During conditions 
of low nutrient availability, eIF4E can be sequestered by 
eIF4E-binding proteins (4E-BP), thus limiting the assem-
bly of the eIF4F complex [41]. The nuclear import of 
eIF4E is mediated by the eIF4E-transporter, binding both 
eIF4E and the nuclear import receptors, importin α/β 
[38, 42]. In the nucleus, eIF4E is known to promote the 
nuclear export of a set of mRNAs [42–45].
In this study, the nuclear localization of eIF2α is cor-
roborated by the finding that the protein sequence con-
tains signals for both import in, and export from, the 
nucleus. Furthermore, structural studies indicate that 
these signals are exposed and available in the phospho-
rylated form of the protein (Fig. 3 and Additional file 2: 
Model 1, Additional file 3: Model 2), justifying the obser-
vation that the nucleus is especially enriched in peIF2α. 
Indeed, recent data suggest that the two domains of the 
eIF2α may move toward or away from each other, switch-
ing from a closed to an open conformation. However, 
the closed conformation is disrupted by phosphoryla-
tion of S51 [34], keeping the protein in a conformational 
“opened” status that exposes the nuclear signals neces-
sary for the entrance and the exit from the nucleus. In 
addition, our results suggest that the transport of this 
factor out of the nucleus could be due to the interac-
tion with NES sequence of the same factor with XPO1, 
as recently reported experimentally by Kirly [35], a well-
known nuclear exporter of cellular proteins and RNAs.
The significance of peIF2α in the nucleus is still unclear. 
However, it is known that eIF2α can be phosphoryl-
ated by several kinases, activated in order to counter-
act adverse cellular conditions in tumors. Accordingly, 
tumor cells develop adaptive responses in order to cope 
with particular conditions of the tumor microenviron-
ment, characterized by stress stimuli and a push to fuel 
continue proliferation. These stress signals induce the 
activation of the unfolded protein response (UPR) [2–4], 
which enables the accumulation of misfolded or unfolded 
proteins in the ER. Responses include an enhanced pro-
tein refolding, degradation of misfolded proteins, and 
translational block, in order to avoid the accumulation 
of proteins entering the ER. Therefore, ER stress, leading 
to eIF2α phosphorylation, inhibits eIF2B, which blocks 
the assembly of the ribosome translation initiation com-
plex, thus reducing the rate of translation initiation [13, 
46]. We have already demonstrated that eIF2α phospho-
rylation and ERK phosphorylation, due to constitutive 
activation of BRAF signaling in V600BRAF-mutated cell 
lines, are correlated. Furthermore, we also found differ-
ent MITF levels in melanoma cell lines harboring BRAF 
mutations, as compared to wtBRAF. Accordingly, lower 
MITF levels in V600BRAF cells [12] (Fig.  3a) can be 
explained by the recently described transcriptional/trans-
lational coupled feedback loop in which MITF increases 
ATF4 transcription, and peIF2α promotes its transla-
tion. After that, MITF transcription and translation are 
blocked, respectively, by ATF4 and peIF2α-mediated 
inhibition of eIF2B [13].
On the other hand, ATF4 upregulation is also induced 
by TFEB, a component of the MITF/TFE family of tran-
scription factors [16]. TFEB has a pivotal role in ER stress 
response and autophagy induction [47]. The high TFEB 
expression in V600BRAF metastatic melanoma cell lines 
found in the present work can be correlated with the high 
LC3II/LC3I ratio reported in Ferretta et  al. [12], in the 
same cell lines, supporting the role of TFEB in autophagy.
Since MITF/TFE factors can regulate lysosomal 
signaling, including Wnt/β-catenin [36], we ana-
lyzed β-catenin levels. We found low β-catenin lev-
els in V600BRAF cell lines, which can be correlated 
to the low MITF levels found in the same cell lines, as 
reported in Ferretta et  al. [12]. Literature reveals that 
signaling through β-catenin enhances MITF expression. 
On the other hand, MITF, depending on its protein lev-
els, can interact with β-catenin (alone or in a complex 
with Lef-1) to activate downstream targets [48]. The 
Fig. 3 Structure of the α subunit of the eIF2α. The figure shows only 
one model of the NMR solution structures reported in the PDB entry 
1Q8 K. A predicted NLS is reported in red, while the NES is reported 
in yellow. The serine residues (S51, S158) discussed in the text are 
highlighted as van der Waals surfaces
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presence of low levels of β-Catenin, associated with low 
MITF levels in V600BRAF melanoma cell lines, could 
be linked to autophagy activation in these cell lines 
[49], as proved by the high TFEB levels revealed in this 
study. Interestingly, I.J. Davis group reported that TFEB 
can rescue MITF knockdown in cell sarcomas [50]. 
According with this study, our results indicate that MiT 
family members can compensate each other for onco-
genic response in V600BRAF cells.
Translational reprogramming has been shown to drive 
gene expression programs leading to metastatic spread 
[13]. Therefore, eIF2α could affect the transcription of 
specific genes, and/or mediate the transport of specific 
mRNAs to the cytoplasm. In addition, eIF2α possesses a 
putative RNA-binding domain, and it has been suggested 
to interact with RNA polymerase [51]. Further studies 
will be performed to evaluate the nuclear eIF2α activity 
and to improve the emerging knowledge relating trans-
lational reprogramming to the invasive phase of mela-
noma, in order to contribute to the development of new 
target treatments for metastatic melanoma.
Conclusions
This is the first report of the nuclear localization of 
peIF2α in metastatic melanoma cell lines.
Our structural studies of eIF2α protein sequence show 
the presence of a predicted bipartited NLS as well as NES 
and an S1 domain. These findings suggest its entry and 
exit in/from the nucleus and its role as a modulating fac-
tor of oncogenic pathways, especially implicated in estab-
lishing and maintaining a metastatic phenotype.
Taken together, our results underpin the key role of 
peIF2α nuclear localization in ER stress response and in 
the invasive phase of melanoma.
Additional files
Additional file 1: Fig. S1. Phosphorylated eIF2α (peIF2α) translation 
factor in V600BRAF cells respectively metastatic (M3) and non-metastatic 
(hmel9) melanoma cell lines.A: Confocal microscopy of localization of 
peIF2α using peIF2α (S51) antibodies.B: Western blotting analyses using 
peIF2α (S51) antibodies were performed on M3 and hmel9 nuclear and 
cytoplasmic fractions. The spot of β-tubulin demonstrates the purity of 
the nuclear and cytoplasmic fractions.
Additional file 2: Model 1. Principal mode analysis of the deposited 
structure shows that the two domains of eIF2α can rotate relative to one 
other, exhibiting a twisting motion.
Additional file 3: Model 2. A bending movement can be observed in 
which the two domains of eIF2α tend to approach (or move away) from 
one other.
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